Project: GT-002 for the treatment of schizophrenia.

The aim is to advance a new drug candidate (GT-002) through Phase 1 clinical studies in healthy volunteers for later development of clinical proof of concept in the treatment of schizophrenia. Healthy male volunteers will first be administered GT-002 in a Single Ascending Dose (SAD) study, combined with assessment of food effects on absorption, followed by a Multiple Ascending Dose (MAD) study. Additional single-dose studies will confirm target engagement with PET imaging and EEG analysis.

Acronym GASH02 (Reference Number: 10687)
Duration 01/03/2016 - 01/03/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24910 Smerud Medical Research International AS Coordinator Norway
24911 Gabather AB Partner Sweden
24912 Pharmaterials Ltd. Partner United Kingdom
24913 Clinical Research Services Turku CRST Partner Finland